Novel peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers
US-2016289296-A1 · Oct 6, 2016 · US
Recombinantly expressed plasmodium CelTOS antigen and methods of use thereof
US9683024B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9683024-B2 |
| Application number | US-201514803583-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 20, 2015 |
| Priority date | Nov 25, 2008 |
| Publication date | Jun 20, 2017 |
| Grant date | Jun 20, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A synthetic nucleotide, which transcribes as the cell-traversal protein for ookinetes and sporozoites (CelTOS) antigen of Malaria Plasmodium , and methods of use thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A synthetic CelTOS polypeptide, said polypeptide encoded by the synthetic nucleotide sequence identified in SEQ ID NO:1. 2. An immunogenic composition comprising the synthetic CelTOS polypeptide of claim 1 . 3. The synthetic polypeptide of claim 1 , wherein said protein is recombinantly expressed with no post-translational N-glycosylation. 4. The immunogenic composition of claim 2 further comprising an adjuvant. 5. A malaria vaccine comprising the synthetic CelTOS polypeptide of claim 1 . 6. The vaccine of claim 5 further comprising an adjuvant. 7. A method for inducing an immune response to Plasmodium malaria in a mammal, comprising administering a composition comprising the synthetic CelTOS polypeptide of claim 1 in an amount effective induce an immune response. 8. The method according to claim 7 wherein the composition further comprises an adjuvant. 9. A method for detecting malaria antibodies in a biological sample, comprising contacting the biological sample with a polypeptide according to claim 1 such that a complex forms between the polypeptide and malaria antibodies in said sample, and detecting the presence or absence of said complex, such that the presence of said complex indicates the presence of malaria antibodies in said sample. 10. A kit for detection of malaria antibodies in a biological sample, comprising the synthetic polypeptide of claim 1 , a buffer or components necessary for producing the buffer, enabling a binding reaction between the polypeptide and malaria antibodies present in the biological sample, and a means for detecting complexes formed in the binding reaction.
Assignees
Inventors
Classifications
Emulsions, e.g. Freund's adjuvant, MF59 · CPC title
characterised by the type of response, e.g. Th1, Th2 · CPC title
- C07K14/445Primary
Plasmodium · CPC title
Antimalarials · CPC title
Immunostimulants · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9683024B2 cover?
- A synthetic nucleotide, which transcribes as the cell-traversal protein for ookinetes and sporozoites (CelTOS) antigen of Malaria Plasmodium , and methods of use thereof.
- Who is the assignee on this patent?
- Angov Evelina, Bergmann-Leitner Elke, Ockenhouse Christian, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/445. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).